BlackRock Health Sciences Trust II offers a balanced biotech and pharma portfolio, with top holdings showing strong FCF margins and positive growth. BMEZ trades at a notable -10% NAV discount, presenting an attractive entry point as sector rotation into healthcare gains momentum. I expect healthcare to outperform through 2026, driven by lower valuations, technological innovation, and defensive positioning during midterm election cycles.
BlackRock Health Sciences Trust II offers exposure to healthcare innovation but faces NAV instability and dividend sustainability concerns. BMEZ's strategy targets high-growth healthcare sectors, leveraging BlackRock's expertise, yet recent performance highlights volatility and risk to distributions. Potential growth in healthcare is supported by industry trends, but BMEZ's NAV fluctuations and payout risks warrant close monitoring.
BlackRock Health Sciences Trust II yields 9.59% but has reduced its monthly payout by 34% to $0.11. BMEZ's NAV and net assets have declined sharply, with net assets dropping 44% over two years and persistent underperformance versus sector peers. Distributions are mostly return of capital (75%), offering tax deferral but eroding investor basis; distribution coverage remains weak at 0.38x.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 50,764 | $878,470.54 | $785,826.72 | -$92,643.82 | -10.55% |
| PER Paul E. Rasmussen SIT INVESTMENT ASSOCIATES Inc. | 271,270 | $3.91M | $4.38M | $474,722.5 | 12.15% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 6,295 | $97,803.85 | $101,664.25 | $3,860.4 | 3.95% |
Daniel L. Lippincott Karpus Management Inc. | 117,615 | $1.69M | $1.89M | $198,769.23 | 11.77% |
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 1,000 | $14,900 | $15,480 | $580 | 3.89% |
| NYSE Exchange | US Country |
BlackRock Health Sciences Term Trust is a distinct entity operating as a closed-end management investment company. Established on August 14, 2019, and based in Wilmington, DE, the Trust's primary mission is to deliver a comprehensive return to its investors. This is achieved through a blend of current income, current gains, and the potential for long-term capital appreciation. The Trust strategically focuses on the health sciences sector, aiming to leverage the growing demand and advancements within this field to generate returns for its investors.
BlackRock Health Sciences Term Trust offers a specialized suite of investment products focused on the health sciences sector, aiming to cater to a wide range of investor needs through: